Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
about
Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifeneClinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophyEffects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidenceOspemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data.Management of Vaginal Atrophy: Implications from the REVIVE Survey.Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopauseEndometrial safety of ospemifene: results of the phase 2/3 clinical development program.Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.Update on alternative therapies for vulvovaginal atrophyThe clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophyOspemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model.Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.Progress in endocrine approaches to the treatment and prevention of breast cancerEffect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophyMaintaining sexual health throughout gynecologic cancer survivorship: A comprehensive review and clinical guide.Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo.Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.Ospemifene in the treatment of vulvovaginal atrophy.Oestrogen replacement in postmenopausal women.Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study.Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy.Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Effects of ospemifene on vaginal epithelium of post-menopausal women.Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study.Tissue selective estrogen complex (TSEC): a review.Therapeutic Approaches to Atrophic Vaginitis in Postmenopausal Women: A Systematic Review with a Network Meta-analysis of Randomized Controlled Trials.Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency
P2860
Q26751149-6554E9FB-BA41-419D-8E74-4FB61D54D5CCQ28066699-3EE9DB10-7FB5-4477-865A-1808C04DF79EQ30380010-ACCBDCCA-8F31-4F86-99C8-ECCB11A16DC0Q30491704-69F6D3BB-C228-46CB-A4DC-66E8215ABA00Q33809618-D2279D30-3377-46BB-B100-DC889A5D8B57Q34532021-5666AE57-5E4E-4D50-B6DF-3B400B5F8A38Q34759968-2440A77B-4829-4784-B401-6A7FC2ADCAC0Q35317535-5BF74DC2-9897-49CD-8E0A-4395270A316AQ35555617-74FF0E57-B20B-4210-AEB6-D547B4EEA9A2Q35626394-5278B88A-EBB9-4520-9193-74FC4548F7D8Q35634204-7AE4B698-D4FB-4A59-A831-2F57B22A6565Q35824414-56B8A15F-6940-44BD-B67B-C55FB1721C06Q36457511-82FEBBE6-2232-4313-8D0E-9AC98029BFE0Q36482360-51753BF5-63CF-419B-83DF-8C0BD7C77E32Q36810368-3DFF15D6-EDD5-4504-9021-DD65673CFE4EQ37091899-EB7DF86E-2E23-423F-9471-D498A3C6F416Q37221035-CB596AF7-E842-46FD-883C-25D6ED9428BDQ37677579-D7B9B0F9-60C6-44DA-A000-A47B6445D44EQ38194966-76CE0006-0603-433D-ACCB-FCFE8EDE4A3BQ38526762-1B9BFF71-C379-4889-941F-F764245A3524Q41110474-95AD7A25-78E2-4927-8DFB-9C75403A2704Q41689276-D4928B52-DD53-4EE4-A8EF-1A2D15229A0AQ45070875-26342A96-8CC5-4D7E-9665-14763721EE81Q47650581-3000E9D9-209F-4DE2-B478-8FFE762AEEDAQ50611000-9C167127-21CF-4612-97B4-1F8C7BECAFF4Q52929113-54A836B3-933C-44BD-8EE4-78E5FE9D7DB5Q53837780-24C06E85-C3FC-44B5-BD5F-8F86839B2F51Q55432577-83CA7FEC-A607-4B51-A574-F3C07E5F2328Q57823053-BD5C13C2-172E-4716-8E20-14721E680183
P2860
Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Ospemifene effectively treats ...... from a pivotal phase 3 study.
@ast
Ospemifene effectively treats ...... from a pivotal phase 3 study.
@en
Ospemifene effectively treats ...... from a pivotal phase 3 study.
@nl
type
label
Ospemifene effectively treats ...... from a pivotal phase 3 study.
@ast
Ospemifene effectively treats ...... from a pivotal phase 3 study.
@en
Ospemifene effectively treats ...... from a pivotal phase 3 study.
@nl
prefLabel
Ospemifene effectively treats ...... from a pivotal phase 3 study.
@ast
Ospemifene effectively treats ...... from a pivotal phase 3 study.
@en
Ospemifene effectively treats ...... from a pivotal phase 3 study.
@nl
P2093
P1433
P1476
Ospemifene effectively treats ...... from a pivotal phase 3 study.
@en
P2093
Gloria A Bachmann
Janne O Komi
Ospemifene Study Group
P304
P356
10.1097/GME.0B013E3181C1AC01
P407
P577
2010-05-01T00:00:00Z